Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03652077
Other study ID # INCAGN 2390-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 24, 2018
Est. completion date August 18, 2021

Study information

Verified date November 2021
Source Incyte Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date August 18, 2021
Est. primary completion date August 18, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants with locally advanced or metastatic tumors who are not eligible for any available therapy likely to convey clinical benefit (locally advanced disease must not be amenable to resection with curative intent). - Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment. - Willingness and ability to safely undergo pretreatment and on-treatment tumor biopsies (core or excisional). - Eastern Cooperative Oncology Group performance status 0 or 1. - Willingness to avoid pregnancy or fathering children based on protocol-defined criteria. Exclusion Criteria: - Laboratory values at screening outside the protocol-defined ranges. - Administration of colony-stimulating factors within 14 days before Study Day 1. - Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug. - Receipt of a live vaccine within 30 days of planned start of study drug. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live-attenuated vaccines and are not allowed. - Active autoimmune disease that required systemic treatment in the past (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). - Known active central nervous system metastases and/or carcinomatous meningitis. - Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year, after treatment with curative intent. - Evidence of active, noninfectious pneumonitis or history of interstitial lung disease. - Active infection requiring systemic therapy. - Evidence of active HBV or HCV infection. - Known history of HIV (HIV 1/2 antibodies). - Known allergy or reaction to any component of study drug or formulation components. - Prior treatment with an anti-TIM-3 antibody for any indication.

Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Merkel Cell
  • Cervical Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Hepatocellular Carcinoma
  • Lung Neoplasms
  • Melanoma
  • Merkel Cell Carcinoma
  • Mesothelioma
  • Mismatch Repair Deficiency
  • MSI
  • Neoplasms
  • Non-small Cell Lung Cancer
  • NSCLC
  • Ovarian Cancer
  • RCC
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Squamous Cell Carcinoma of the Head and Neck
  • Stomach Cancer
  • Stomach Neoplasms
  • Triple Negative Breast Neoplasms
  • Triple-negative Breast Cancer
  • Urothelial Carcinoma
  • Uveal Melanoma

Intervention

Drug:
INCAGN02390
Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.

Locations

Country Name City State
United States Hackensack Medical Center Hackensack New Jersey
United States Carolina BioOncology Huntsville North Carolina
United States University of Mississippi Jackson Mississippi
United States The Angeles Clinical and Research Institute Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of treatment-emergent adverse events Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. Up to 12 months
Primary Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only) PAD defined as a dose that achieves a level of receptor occupancy considered to be biologically active. Up to approximately 1 month
Secondary Cmax of INCAGN02390 Maximum observed plasma or serum concentration. Up to 12 months
Secondary Tmax of INCAGN02390 Time to maximum concentration. Up to 12 months
Secondary Cmin of INCAGN02390 Minimum observed plasma or serum concentration over the dose interval. Up to 12 months
Secondary AUC0-t of INCAGN02390 Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t. Up to 12 months
Secondary Objective response rate Defined as the percentage of participants having complete response (CR) or partial response (PR) determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Up to 12 months
Secondary Duration of response Defined as time from earliest date of disease response (CR or PR) until earliest date of disease progression (determined by investigator assessment of radiographic disease per RECIST v1.1) or death from any cause, if occurring sooner than progression. Up to 12 months
Secondary Disease control rate Defined as percentage of participants having CR, PR, or stable disease as best on-study response. Up to 12 months
Secondary Progression-free survival Defined as the time from date of first dose of study drug until the earliest date of disease progression (determined by investigator assessment of objective radiographic disease per RECIST v1.1) or death from any cause if occurring sooner than progression. Up to 12 months
Secondary Level of binding of INCAGN02390 to TIM-3 Assessed from participant whole blood samples. Up to approximately 3 months
Secondary Immunogenicity of INCAGN02390 Defined as the occurrence of specific ADA to INCAGN02390. Up to 12 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2